

# **Grading report**

April 29, 2025, | Mumbai

Crisil assigns
Fund Management Grading – 1
to Somerset Indus Healthcare
India Fund III – Scheme I



Crisil has assigned **Fund Management Grading – 1** to Somerset Indus Healthcare India Fund III – Scheme I, a Category II alternative investment fund (AIF) managed by Somerset Healthcare Investment Advisors III Pvt Ltd.

Schemes graded 'Crisil Fund Management Grading – 1' are judged to follow '**very strong**' standards in investment processes and management practices.

## About the fund

Somerset Indus Healthcare India Fund III is an AIF that has been established as a trust under provisions of the Indian Trusts Act, 1882. It is registered with Securities and Exchange Board of India (SEBI) as a Category II AIF. Somerset Indus Healthcare India Fund III – Scheme I is the first scheme under this AIF which has been formed with the purpose of making investments in small and mid-sized Indian companies providing services and products mainly in Tier II and Tier III regions in the healthcare sector, including pharmaceuticals, biotech, medical devices, diagnostics, tech-driven and healthcare delivery models. The term of the fund is 10 years from the initial closing. The target corpus of the fund is Rs 2,000 crore (including a greenshoe option of Rs 400 crore). The fund announced its initial close in August 2024.

SICP Investment Advisors India LLP is the sponsor of the fund, Somerset Healthcare Investment Advisors III Pvt Ltd is the investment manager, and Orbis Trusteeship Services Pvt Ltd is the trustee.

The fund has been set up as a master feeder structure. One of the founders of Somerset (through an investment entity) and a US based investment firm that specialises in healthcare investments serve as sponsors to the feeder fund. The US based investment firm primarily invests in the US and European markets.



## **Detailed rationale**

The grading reflects the extensive experience of the leadership team in the private equity space and their strong understanding of India's healthcare and related sectors, which complements the fund's investment strategy. This is reinforced by a strong investment and post-investment monitoring processes, defined roles and responsibilities of team members and transparency in client communication.

The management team comprises five members, including four investment partners and the CFO, with an average experience of 27 years. The sponsors have contributed ~10% of the total commitment in the fund which is much higher than the minimum regulatory requirement.

The fund has a defined investment policy that governs all activities from deal sourcing to evaluation, due diligence and investment decision making. The investment team comprises 10 members with relevant experience in private equity investment management. The four investment partners have combined overall experience of more than 125 years and have developed expertise in leading deals. The team, in addition to its proprietary network, also sources deals, from intermediaries. The investment team conducts its own business diligence and is ably supported by independent agencies to conduct commercial; financial; legal; environmental, social and governance (ESG); and integrity due diligence. The team consults external domain experts on an as-needed basis to provide additional insights and expertise during post-investment monitoring stages.

The investment decisions are made by the investment committee which comprises three members – two co-founders and one representative from the US based investment firm. The investment process includes initial screening followed by detailed analysis and third-party diligence before arriving at a final decision in the committee meetings. Divestment-related decisions are also approved by the committee. The team, like its previous fund, plans to form a limited partner advisory committee to review and approve transactions involving conflicts of interest and key terms of the fund including extension of commitment period, change in key personnel, change in investment limits among others.

The operations and finance team headed by the CFO comprises five members, which aids the investment team in transaction support and post-investment monitoring. The finance and operation team are supported by external agencies for post - investment valuations, accounting, taxation, legal, regulatory, governance and board matters.

The fund has implemented transparent client communication and disclosure procedures. It shares quarterly updates with investors, which include a fund overview, business updates, initiatives taken by the fund and financial and operational metrics of the investee companies along with their valuations. It holds quarterly meetings with the investors in addition to the annual investor meeting.

Somerset Indus healthcare has previously managed two healthcare funds with different fund structures. The first fund was an offshore fund that delivered a gross internal rate of return (IRR) of 26.3% in rupee terms as of December 2024, with one investment yet to exit. This fund has taken a total extension of four years. The second fund has a co-investment structure with an onshore fund being registered as an AIF with SEBI. As of December 2024, it has generated a gross IRR of 16.2%.



# **Scoring model**

The schemes are assigned scores on a five-point scale, ranging from Fund Management Grading -1 to Fund Management Grading -5.

Grading level	Definition
Fund Management Grading – 1	The scheme follows <b>very strong</b> standards in investment processes and management practices
Fund Management Grading – 2	The scheme follows <b>strong</b> standards in investment processes and management practices
Fund Management Grading – 3	The scheme follows <b>adequate</b> standards in investment processes and management practices
Fund Management Grading – 4	The scheme follows <b>below average</b> standards in investment processes and management practices
Fund Management Grading – 5	The scheme follows <b>weak</b> standards in investment processes and management practices

Link to related criteria: Fund management grading methodology



#### **About Crisil**

Crisil is a global, insights-driven analytics company. Our extraordinary domain expertise and analytical rigour help clients make mission-critical decisions with confidence.

Large and highly respected firms partner with us for the most reliable opinions on risk in India, and for uncovering powerful insights and turning risks into opportunities globally. We are integral to multiplying their opportunities and success.

Headquartered in India, Crisil is majority owned by S&P Global.

Founded in 1987 as India's first credit rating agency, our expertise today extends across businesses: Crisil Ratings, Crisil Intelligence, Crisil Coalition Greenwich and Crisil Integral IQ.

Our globally diverse workforce operates in the Americas, Asia-Pacific, Europe, Australia and the Middle East, setting the standards by which industries are measured.

For more information, visit www.Crisil.com

Connect with us: LinkedIn | Twitter

## About Regulated Research provided by Crisil Limited

Crisil Limited is registered as a Research Analyst with SEBI (Registration No INH000007854), herein referred to as "Crisil Intelligence". We provide insights, opinion, analysis, and data on the Indian economy, industry, capital markets, and companies.

We are the largest valuation agency for fixed income securities, and a prominent debt and hybrid index provider in India. We publish rankings for mutual fund schemes, and provide granular portfolio analysis services for asset managers, financial intermediaries, retirement funds and institutional investors.

Our data and analytics platforms - Alphatrax and Quantix - enable our clients to assess Industry and Company level risks based on Crisil's proprietary models.

Our Company reports (that combine select financial and non-financial data, analytics from our proprietary risk models, and commentary on company's financial performance) are used by commercial banks, financial institutions, and non-banking finance companies as part of their credit/ risk management process.

Our SME Gradings, used by lenders, assess creditworthiness of SME enterprises relative to the peers leveraging our proprietary grading model. The framework includes assessment of entity-level financial and operating performance, as well as industry-level drivers.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Investment in securities market are subject to market risks. Read all the related documents carefully before investing For additional disclosures please click on this <u>link</u>

### Crisil privacy statement

Crisil respects your privacy. We may use your personal information, such as your name, location, contact number and email id to fulfil your request, service your account and to provide you with additional information from Crisil. For further information on Crisil's privacy policy please visit https://www.crisil.com/content/crisilcom/en/home/crisil-privacy-notice.html

### **Analyst Disclosure**

Notwithstanding any member(s) of the team, Crisil are involved in the preparation of this Report and/or Crisil names are published as part of this Report and their relatives, having financial interest or actual/ beneficial ownership in the form of securities holding (of less than 1%), at an individual level, if any, with any of the members having served as officers, directors, or employees of the companies in the last 6 months or having engaged in market making activities, in the subject companies, there exists no material conflict of interest which can affect the neutrality or bias the output of the Report, given the deployed procedural safeguards including but not limited to objective methodology followed in the process of execution with no influence at an analyst level and the outputs being executed at a portfolio level, with no separate analysis for an individual company.

Members of the team (including their relatives) involved in the preparation of this report and whose names are published as part of this report, as may be required, hereby affirm that

- 1. There exists no conflict of interest (including any financial interest or actual/ beneficial ownership of 1% or more of the securities of the subject companies) that can bias the output of the Report.
- 2. Neither the members have served as officers, directors, or employees of the companies analyzed in the report in the last 6 months nor have they engaged in market making activities for the subject companies.
- 3. None of the members of the team involved in the preparation of this report have received any compensation whatsoever from the subject company or third party in the past twelve months in connection with the research report.

None of the members involved in the preparation of this report have managed or co-managed public offering of securities for the subject company in the past twelve months

#### **Terms and Conditions**

This Report is based on data publicly available or from sources considered reliable. Crisil Intelligence does not represent that the Report is accurate or complete and hence, it should not be relied upon as such. Opinions expressed herein are our current opinions as on the date of this report. Nothing in this report constitutes investment, legal, accounting or tax advice or any solicitation, whatsoever. The subscriber/ user assumes the entire risk of any use made of this data/ report. Crisil especially states that, it has no financial liability whatsoever, to the subscribers/ users of this report.

This Report is additionally subject to your contractual terms with Crisil.

The report is for use within the jurisdiction of India only. Nothing in this report is to be construed as Crisil providing, or intending to provide, any services in other jurisdictions where Crisil does not have the necessary permissions and/ or registration to carry out its business activities. The user will be solely responsible for ensuring compliance for use of the report, or part thereof, outside India. Crisil Limited operates independently of, and does not have access to information obtained by Crisil Ratings Limited, which may, in their regular operations, obtain information of a confidential nature. The views expressed in this Report are that of Crisil Intelligence, and not of Crisil Ratings Limited.

### **Company Disclosure**

- 1. Crisil Intelligence or its associates do not provide investment banking or merchant banking or brokerage or market making services.
- Crisil Intelligence encourages independence in research report preparation and strives to minimize conflict in preparation of research reports through strong governance architecture comprising of policies, procedures, and disclosures.
- Crisil Intelligence prohibits its analysts, persons reporting to analysts, and their relatives from having any financial interest in the securities or derivatives of companies that the analysts cover.
- Crisil Intelligence or its associates collectively may own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.
- Crisil Intelligence or its associates may have financial interest in the form of holdings in the subject company mentioned in this report.
- Crisil receives compensation from the company mentioned in the report or third party in connection with preparation of the research 6.
- As a provider of ratings, grading, data, research, analytics and solutions, infrastructure advisory, and benchmarking services, Crisil or its associates are likely to have commercial transactions with the company and may receive compensation for the services
- Crisil Intelligence or its associates do not have any other material conflict of interest at the time of publication of the report.
- No material disciplinary action has been taken against Crisil Intelligence or its analysts by any Regulatory Authority impacting Research Analyst activities.

#### **Disclaimer**

The Grading is a one-time exercise and the grading will not be kept under surveillance. An accepted Grading may be used and disseminated only for a period of twelve (12) months from the Initial Grading communication date by the client. Each Grading shall be the sole property of Crisil. Crisil shall, at all times, exclusively own any and all intellectual property rights in the Grading. No Crisil Grading/ Grading Report may be copied, retransmitted or redistributed in any manner except for licensed usage (Permitted Use herein) agreed with Crisil. While Crisil uses reasonable care in arriving at the Grading and bases its grading on data and information that it considers reliable, Crisil does not warrant that any Grading is error-free, complete, adequate or without faults. Crisil explicitly states that it relies on the data received from the asset manager, on an 'as is' basis to arrive at the Grading. Crisil does not conduct any independent due diligence on the authenticity or accuracy thereof and disclaims any liability in this regard. The grading does not constitute an audit of the organisation by Crisil. The grading is also not a recommendation to enter into or not enter into any transaction with the organisation and is not an assurance/guarantee of the targeted returns of the fund mentioned by the asset manager. Anyone accessing and/or using the Grading does so subject to the condition that: (a) Crisil is not responsible for any errors, omissions or faults with respect to any Grading or for the results obtained from the use of the Grading; (b) Crisil expressly excludes all liability arising from or relating to their use of the Grading. It is especially stated that Crisil, its Directors, Grading Committee members, employees and others associated with the grading assignment do not have any financial liability whatsoever to the users of this grading and/or grading report. You acknowledge that the Grading represents Crisil's independent opinion based on, among other things, information made available by the asset manager and information that Crisil obtains from sources considered reliable. In doing so, Crisil does not act as an "expert" under any law or regulation and You may not name Crisil as such.

EXCEPT FOR THE FOREGOING, THERE ARE NO OTHER WARRANTIES OR REPRESENTATIONS OF WHATEVER NATURE, WHETHER EXPRESS OR IMPLIED INCLUDING, WITHOUT LIMITATION, WARRANTIES OF FITNESS OF PURPOSE, OR THAT THE SERVICES ARE ERROR-FREE OR WILL BE PROVIDED WITHOUT INTERRUPTION.

